Diagnosis of HER2 Cancers

Brain mets

What is HER2 ?

The human epidermal growth factor receptor 2 (HER2) is a growth-promoting protein on the outside of all breast cells. Breast cancer cells with higher than normal levels of HER2 are called HER2-low or positive. These cancers tend to grow and spread faster than other breast cancers. However, they are also much more likely to respond to treatment with drugs that target the HER2 protein.

Until end of 2022, only HER2-positive breast (and gastric) cancer patients received HER2 targeted treatment. All other patients were considered as being HER2-negative. Recently, HER2 classification was refined into three categories:
HER2-positive, HER2-low and HER2-negative/null/zero


  • Tumor characterization
  • Early diagnosis of patients suffering from HER2 cancer, including HER2-low
  • Mapping of HER2 heterogeneity
  • Follow-up of patients diagnosed with HER2 metastases

Following ABSCINT-HER2

  • Treatment adaptation (HER2-targeted therapy, kinase inhibitors that cross the blood-brain barrier)
  • Stereotactic radiosurgery guidance
  • Follow-up of and detection of recurrence

Our solution

Direct detection of HER2 cells throughout the body, including in the brain